Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URM002
MIFTS: 52

Uremia

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Uremia

About this section

MalaCards integrated aliases for Uremia:

Name: Uremia 12 76 55 44 15 73
Uremia of Renal Origin 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4676
ICD10 33 N19
MeSH 44 D014511
UMLS 73 C0041948
Sources

Summaries for Uremia

About this section
MalaCards based summary : Uremia, also known as uremia of renal origin, is related to peritonitis and hyperphosphatemia. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Parathyroid hormone synthesis, secretion and action. The drugs Gabapentin and Fexofenadine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 76 Uremia is the condition of having \"urea in the blood\". Urea is one of the primary components of urine.... more...

Sources

Related Diseases for Uremia

About this section

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 peritonitis 30.9 ALB B2M CRP
2 hyperphosphatemia 30.5 CASR PTH VDR
3 arteriosclerosis 30.3 CRP INS SPP1
4 hyperparathyroidism 30.2 CASR EPO PTH TNFRSF11B VDR
5 renal osteodystrophy 30.1 CASR PTH TNFRSF11B VDR
6 multiple endocrine neoplasia, type i 30.0 CASR INS PTH
7 sleep apnea 29.9 CRP INS LEP
8 pancreatitis 29.7 CASR CRP LPL
9 primary hyperparathyroidism 29.7 ALB CASR PTH VDR
10 secondary hyperparathyroidism of renal origin 29.7 ALB CASR EPO PTH TNFRSF11B VDR
11 hyperglycemia 29.6 ALB INS LEP
12 arteries, anomalies of 29.6 ALB CRP INS LEP VWF
13 insulin-like growth factor i 29.6 GHR INS LEP
14 liver disease 29.1 ALB INS LEP TF
15 bone disease 28.9 B2M CASR PTH SPP1 TNFRSF11B VDR
16 diabetes mellitus 28.9 ALB CRP EPO INS LEP RETN
17 vascular disease 27.9 ALB CRP INS LPL RETN TNFRSF11B
18 coronary heart disease 1 27.6 APOC3 CRP INS LPL RETN
19 heart disease 27.5 ALB APOC3 CRP INS LPL VWF
20 myocardial infarction 27.4 ALB APOC3 CRP INS RETN VWF
21 hypertension, essential 27.4 ALB CRP INS LEP LPL RETN
22 kidney disease 27.2 ALB B2M CASR CRP EPO INS
23 coronary artery anomaly 26.9 APOC3 CRP INS LPL RETN TNFRSF11B
24 chronic kidney failure 26.5 ALB B2M CASR CRP EPO INS
25 diabetes mellitus, noninsulin-dependent 25.6 AHSG ALB APOC3 CRP INS LEP
26 nephronophthisis 1 11.1
27 malignant otitis externa 10.9 CRP INS
28 hemolytic-uremic syndrome 10.9
29 euthyroid sick syndrome 10.9
30 severe nonproliferative diabetic retinopathy 10.9 ALB INS
31 abdominal tuberculosis 10.8 ALB CRP
32 immunodeficiency 43 10.8 ALB B2M
33 pyuria 10.8 ALB CRP
34 scleredema adultorum 10.8 INS PTH
35 fetal erythroblastosis 10.8 ALB EPO INS
36 fibrogenesis imperfecta ossium 10.8 PTH TNFRSF11B
37 burns 10.7 ALB INS
38 fanconi-like syndrome 10.7 B2M CASR
39 hemorrhagic fever with renal syndrome 10.6 ALB B2M CRP
40 hypervitaminosis d 10.6 PTH VDR
41 hypocalciuric hypercalcemia, familial, type iii 10.6 CASR PTH
42 uremic neuropathy 10.6 B2M EPO PTH
43 carotid stenosis 10.6 CRP SPP1 TNFRSF11B
44 lipodystrophy, familial partial, type 2 10.6 INS LEP
45 intermittent claudication 10.6 ALB CRP VWF
46 chronic ulcer of skin 10.6 ALB CRP
47 coronary stenosis 10.6 ALB CRP VWF
48 hyperlipoproteinemia, type v 10.6 INS LPL
49 xanthinuria, type i 10.5 CASR SPP1 VDR
50 osteitis fibrosa 10.5 B2M CASR PTH

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia
Sources

Symptoms & Phenotypes for Uremia

About this section

MGI Mouse Phenotypes related to Uremia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 EPO B2M GHR CASR AHSG ALB
2 cellular MP:0005384 10.35 EPO B2M GHR CASR ALB LPL
3 cardiovascular system MP:0005385 10.33 EPO B2M GHR CRP PTH LEP
4 growth/size/body region MP:0005378 10.27 B2M AHSG CASR LPL INS PTH
5 hematopoietic system MP:0005397 10.26 EPO B2M CASR INS PTH LEP
6 immune system MP:0005387 10.25 CRP EPO B2M GHR CASR INS
7 endocrine/exocrine gland MP:0005379 10.11 ALB B2M CASR INS PTH GHR
8 mortality/aging MP:0010768 10.1 EPO B2M CASR ALB LPL INS
9 digestive/alimentary MP:0005381 10.07 ALB B2M CASR INS LEP VWF
10 integument MP:0010771 10.06 EPO B2M CASR LPL INS LEP
11 liver/biliary system MP:0005370 9.97 EPO B2M GHR ALB LPL INS
12 limbs/digits/tail MP:0005371 9.91 EPO AHSG PTH LEP GHR TNFRSF11B
13 muscle MP:0005369 9.85 EPO GHR CASR AHSG ALB LEP
14 renal/urinary system MP:0005367 9.5 ALB CASR INS LEP GHR SPP1
15 skeleton MP:0005390 9.32 EPO CASR AHSG INS PTH LEP
Sources

Drugs & Therapeutics for Uremia

About this section

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
2
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
5
Metformin Approved Phase 4 657-24-9 14219 4091
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Pamidronate Approved Phase 4 40391-99-9 4674
8
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
9
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
10
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
11
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
12 tannic acid Approved, Nutraceutical Phase 4
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Histamine Phosphate Phase 4 51-74-1 65513
15 Analgesics Phase 4,Phase 3,Not Applicable
16 calcium channel blockers Phase 4,Not Applicable
17 Central Nervous System Depressants Phase 4,Not Applicable
18 Neurotransmitter Agents Phase 4,Not Applicable
19 Histamine Antagonists Phase 4
20 Histamine H1 Antagonists Phase 4
21 Histamine H1 Antagonists, Non-Sedating Phase 4
22 Hormone Antagonists Phase 4,Phase 2,Not Applicable
23 Tranquilizing Agents Phase 4,Not Applicable
24 Hormones Phase 4,Phase 2,Not Applicable
25 Anti-Allergic Agents Phase 4
26 Anti-Anxiety Agents Phase 4,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
28 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
29 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anticonvulsants Phase 4,Not Applicable
31 Psychotropic Drugs Phase 4,Not Applicable
32 Calcium, Dietary Phase 4,Not Applicable
33 Micronutrients Phase 4,Phase 2
34 Hematinics Phase 4
35 Trace Elements Phase 4,Phase 2
36 Dialysis Solutions Phase 4,Phase 3,Phase 2
37 Vasodilator Agents Phase 4
38 Vitamin B Complex Phase 4
39 Hypoglycemic Agents Phase 4,Phase 2
40 Vitamins Phase 4,Phase 2
41 Polymethyl Methacrylate Phase 4
42 Incretins Phase 4
43 Antioxidants Phase 4,Phase 1,Phase 2
44 Protective Agents Phase 4,Phase 1,Phase 2
45 Folate Nutraceutical Phase 4
46 Vitamin B9 Nutraceutical Phase 4
47
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
48
Nafamostat Approved, Investigational Phase 3 81525-10-2
49
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
50
protease inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Probiotics Use in the Chronic Peritoneal Dialysis Patients Unknown status NCT01076426 Phase 4 Pro-biotics
2 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
3 Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events Completed NCT00317005 Phase 4 folate treatment
4 Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
7 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
8 Hannover Dialysis Outcome Study Completed NCT00529139 Phase 4
9 Very Low Protein Diet or Dialysis in Uremic Elderly? Completed NCT00388648 Phase 4 mixture of amino and keto acids
10 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
11 Liraglutide Treatment to Patients With Severe Renal Insufficiency Completed NCT01394341 Phase 4 Liraglutide
12 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
13 STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE Completed NCT00278057 Phase 4 dialysisis with and without glucose in the dialysis
14 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
15 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
16 Nafamostat Efficacy and Safety in Critically Ill Patients(NICE) Unknown status NCT01486485 Phase 3 heparinized saline priming group;nafamostat infusion after heparinized saline priming
17 The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
18 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
19 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
20 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
21 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
22 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT02949128 Phase 3
23 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Recruiting NCT02205541 Phase 3 Eculizumab;Placebo
24 Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Not yet recruiting NCT02976688 Phase 2, Phase 3
25 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
26 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
27 Effect of SVF Derived MSC in DCD Renal Transplantation Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
28 Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
29 Effect of BM-MSCs in DCD Kidney Transplantation Unknown status NCT02561767 Phase 1, Phase 2 Induction therapy (ATG or Basiliximab);Maintenance therapy (Low-dose CNI + MPA + steroids)
30 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
31 Induction With SVF Derived MSC in Living-related Kidney Transplantation Unknown status NCT02492308 Phase 1, Phase 2 Basiliximab induction
32 Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Unknown status NCT01876017 Phase 1, Phase 2
33 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
34 L-Cysteine in Peritoneal Dialysis Completed NCT02050139 Phase 2
35 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
36 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
37 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
38 Role of Turmeric on Oxidative Modulation in ESRD Patients Completed NCT01906840 Phase 1, Phase 2 Turmeric;placebo
39 Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Completed NCT00309257 Phase 2 ACE I, ATA II and Statins;Benazepril, Valsartan and Fluvastatin
40 Sevelamer in Proteinuric CKD Completed NCT01968759 Phase 2 Sevelamer;Ramipril and Irbesartan
41 A Study in Participants With End-Stage Renal Disease Completed NCT01200290 Phase 2 LY2127399
42 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
43 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
44 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
45 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
46 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
47 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab
48 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT00838513 Phase 2 eculizumab
49 A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03303313 Phase 2 Cemdisiran
50 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Not yet recruiting NCT03518203 Phase 2 Eculizumab

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: uremia

Sources

Genetic Tests for Uremia

About this section
Sources

Anatomical Context for Uremia

About this section

MalaCards organs/tissues related to Uremia:

41
Kidney, Testes, Endothelial, Bone, Monocytes, Liver, Neutrophil
Sources

Publications for Uremia

About this section

Articles related to Uremia:

(show top 50) (show all 709)
# Title Authors Year
1
Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. ( 29304096 )
2018
2
RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. ( 29529595 )
2018
3
Uremia: A historical reappraisal of what happeneda8c. ( 29451473 )
2018
4
Carmelo Giordano (1930-2016): uremia therapy by low protein alimentation and sorbents. ( 29482271 )
2018
5
Risk factors of the peptic ulcer bleeding in aging uremia patients under regular hemodialysis. ( 29778548 )
2018
6
CRP, ILa892 and TNFa89I+ level in patients with uremia receiving hemodialysis. ( 29257244 )
2018
7
Evaluation of carotid artery elasticity in patients with uremia by echo tracking. ( 29453675 )
2018
8
The function of the parathyroid oxyphil cells in uremia: still aA mystery? ( 29055426 )
2017
9
Evaluation of the different surgical parathyroidectomieson secondary hyperparathyroidism in uremia patients. ( 29205012 )
2017
10
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28376076 )
2017
11
Serpiginous cranial arterial calcification in uremia. ( 28972106 )
2017
12
Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. ( 28680087 )
2017
13
Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. ( 28523279 )
2017
14
"Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia. ( 28524108 )
2017
15
Sudden bilateral vision loss as the sole manifestation of posterior reversible encephalopathy syndrome from acute uremia: Clinical case report. ( 28682904 )
2017
16
Asymptomatic Brain Edema after Hemodialysis Initiation in a Patient with Severe Uremia. ( 28553356 )
2017
17
Uremia ( 28722889 )
2017
18
Uremia does not affect neointima formation in mice. ( 28747676 )
2017
19
Simultaneous liver, pancreas-duodenum and kidney transplantation in a patient with hepatitis B cirrhosis, uremia and insulin dependent diabetes mellitus. ( 29259387 )
2017
20
Persistence of Vascular Calcification after Reversal of Uremia. ( 27939134 )
2017
21
Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction. ( 28605780 )
2017
22
Skin Blood Flow and Vascular Endothelium Function in Uremia. ( 29056167 )
2017
23
Influence of SPK with Enteric Drainage on the Pancreatic Exocrine Function in Diabetic Patients with Uremia. ( 29138633 )
2017
24
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 29040261 )
2017
25
A History of Uremia Research. ( 29056163 )
2017
26
Research progress about effects of myocardial enzyme and troponin on uremia with acute left ventricular failure. ( 28338189 )
2017
27
CORRIGENDUM: Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28832560 )
2017
28
Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. ( 28341272 )
2017
29
Uremia modulates the phenotype of aortic smooth muscle cells. ( 28107707 )
2017
30
Proceedings of the Ninth International Congress of Uremia Research and Toxicity. ( 29056162 )
2017
31
Risk factors for cardiovascular disease in children on chronic hemodialysis - Uremia related (non-traditional) risk factors, part II. ( 29350892 )
2017
32
Bilateral rectal sheath hematomas after low-molecular weight heparin treatment in uremia. ( 28330422 )
2017
33
The Evolving Patterns of Uremia: Unmet Clinical Needs in Dialysis. ( 28910786 )
2017
34
Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia. ( 28050009 )
2017
35
Relationship between serum total bilirubin levels and mortality in uremia patients undergoing long-term hemodialysis: A nationwide cohort study. ( 28892712 )
2017
36
Aphasic Status Epilepticus Associated with Uremia. ( 29344470 )
2017
37
ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. ( 28351665 )
2017
38
Uremia Retention Molecules and Clinical Outcomes. ( 28910788 )
2017
39
Urea transporters and sweat response to uremia. ( 27273880 )
2016
40
Back to the future: restricted protein intake for conservative management of CKD, triple goals of renoprotection, uremia mitigation, and nutritional health. ( 26886110 )
2016
41
Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. ( 26765403 )
2016
42
Effectiveness of posthemodialysis administration of pregabalin (75 mg) in treatment resistance uremia pruritus. ( 26957874 )
2016
43
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. ( 27992874 )
2016
44
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. ( 26831434 )
2016
45
Development of Acute Pericarditis Associated with New-onset Rheumatoid Arthritis in a Diabetic Patient with Renal Impairment: The Elusive Nature of Uremia. ( 27086811 )
2016
46
Inhibiting post-translational core fucosylation prevents vascular calcification in the model of uremia. ( 27521658 )
2016
47
Uremia-caused changes of ghrelin system in hippocampus may be associated with impaired cognitive function of hippocampus. ( 26861060 )
2016
48
Uremia-Associated Premature Ageing Of T Cells Does Not Predict Infectious Complications After Renal Transplantation. ( 26914971 )
2016
49
Comparing classification performance of several types of significant genes to identify key genes in uremia. ( 27383319 )
2016
50
Comparison of HLA-A, -B and -DRB1 Loci Polymorphism between Kidney Transplants of Uremia Patients and Healthy Individuals in Central China. ( 27780235 )
2016
Sources

Variations for Uremia

About this section
Sources

Expression for Uremia

About this section
Search GEO for disease gene expression data for Uremia.
Sources

Pathways for Uremia

About this section

Pathways related to Uremia according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.73 EPO GHR INS SPP1 VWF
2
Parathyroid hormone synthesis, secretion and action 37
11.68 CASR PTH VDR
3
HIF-1 signaling pathway 37
11.63 EPO INS TF
4
Adipogenesis 1
11.38 INS LEP LPL RETN
5
Endochondral Ossification 1
11.36 GHR PTH SPP1
6
HIF-1-alpha transcription factor network 1
11.31 EPO LEP TF
7
Differentiation Pathway 1
11.11 EPO INS TF
8
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
10.92 PTH SPP1 VDR
9
Osteoclast Signaling 1
10.7 SPP1 TNFRSF11B
10
Osteoblast Signaling 1
10.58 PTH TNFRSF11B
11
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.58 PTH SPP1 TNFRSF11B VDR
12
Vitamin D Metabolism 1
10.4 PTH VDR
Sources

GO Terms for Uremia

About this section

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 AHSG ALB APOC3 B2M CRP EPO
2 extracellular matrix GO:0031012 9.73 AHSG APOC3 LPL VWF
3 cell surface GO:0009986 9.73 B2M CASR EPO GHR LPL TF
4 secretory granule lumen GO:0034774 9.65 AHSG INS TF
5 endoplasmic reticulum lumen GO:0005788 9.63 AHSG ALB B2M INS SPP1 TF
6 platelet alpha granule lumen GO:0031093 9.58 AHSG ALB VWF
7 extracellular space GO:0005615 9.5 AHSG ALB APOC3 B2M CRP EPO
8 chylomicron GO:0042627 9.46 APOC3 LPL
9 HFE-transferrin receptor complex GO:1990712 9.37 B2M TF
10 extracellular exosome GO:0070062 10.02 AHSG ALB APOC3 B2M CRP LPL

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 B2M LPL PTH TNFRSF11B
2 cellular calcium ion homeostasis GO:0006874 9.76 CASR PTH VDR
3 cholesterol homeostasis GO:0042632 9.75 APOC3 LPL VDR
4 response to nutrient GO:0007584 9.74 EPO LEP TNFRSF11B
5 response to insulin GO:0032868 9.72 INS LEP RETN
6 skeletal system development GO:0001501 9.71 AHSG PTH TNFRSF11B VDR
7 regulation of signaling receptor activity GO:0010469 9.7 EPO INS LEP PTH RETN SPP1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 EPO GHR LEP
9 response to nutrient levels GO:0031667 9.67 INS LEP PTH
10 hormone metabolic process GO:0042445 9.63 GHR LEP
11 negative regulation of lipid catabolic process GO:0050995 9.63 APOC3 INS
12 high-density lipoprotein particle remodeling GO:0034375 9.62 ALB APOC3
13 iron ion transport GO:0006826 9.62 B2M TF
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.61 INS LEP
15 positive regulation of glycogen biosynthetic process GO:0045725 9.6 INS PTH
16 intestinal absorption GO:0050892 9.59 LEP VDR
17 negative regulation of blood vessel diameter GO:0097756 9.56 CRP INS
18 platelet degranulation GO:0002576 9.56 AHSG ALB TF VWF
19 negative regulation of lipid storage GO:0010888 9.54 CRP LEP
20 retina homeostasis GO:0001895 9.54 ALB B2M TF
21 chylomicron remodeling GO:0034371 9.52 APOC3 LPL
22 negative regulation of feeding behavior GO:2000252 9.48 INS RETN
23 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
24 cellular response to iron ion GO:0071281 9.43 B2M TF
25 regulation of iron ion import GO:1900390 9.32 B2M TF
26 acute-phase response GO:0006953 9.26 AHSG CRP EPO INS
27 cellular protein metabolic process GO:0044267 9.1 AHSG ALB B2M INS SPP1 TF

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB B2M CRP GHR INS VWF
2 hormone activity GO:0005179 9.02 EPO INS LEP PTH RETN
3 peptide hormone receptor binding GO:0051428 8.96 LEP PTH
Sources

Sources for Uremia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....